Build-Out Adds 21,000+ Square Feet of Lab and Office Space to Existing Facilities to Further Increase Efficiencies and Services Capacity
JULY 9, 2019—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has completed the latest expansion of its Durham, NC campus, which serves as the company’s USA headquarters, with the opening of an additional 21,173 square foot building directly adjacent to its existing facility. The build-out, which followed a previous expansion in late 2017 that added nearly 21,000 square feet to the same site, brings the campus’ total footprint to over 69,000 square feet.
Nearly 8,000 square feet of the new building is dedicated GxP laboratory space and through its highly efficient design more than doubles the capacity for all bioanalytical services BioAgilytix offers, including those involving cell-based assays, biomarkers, pharmacokinetics, and immunogenicity testing in support of large molecule biotherapeutics as well as cell and gene therapy. “This expansion was necessary to support our customers’ continually growing need for large molecule bioanalysis and our ability to continue to hire exceptional scientific talent that can meet their complex demands,” said Mark Bethers, Global Vice President of Human Resources of BioAgilytix. “The new building, which shares a common lot with our current facility, presented the perfect opportunity for us to add state-of-the-art lab space and will allow us to further leverage our capacity and resources in Durham to efficiently support global studies.” The expansion also adds to BioAgilytix’s GMP lab capacity, explained Bethers. “We now have the space to grow our existing GMP lab as we can move non-GMP work as needed to the new lab facility, giving us the capacity to scale any and all of our services with customer demand.”
“As our reputation for scientific excellence and service quality has grown, so have the project requests from our customers – whether they are existing clients turning to us with additional large molecule studies or new sponsors that have challenging assays requiring specialized expertise,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Last year alone, our team supported 8 of the 18 large molecule drugs that were approved by the FDA. The campus expansion will ensure we can continue to meet customers’ bioanalytical needs efficiently, effectively, and with robust and timely results that help accelerate their innovative breakthroughs to market.”
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.